Pacritinib

CAS: 937272-79-2

Ref. 3D-MMB27279

Produktinformation

• Name: Pacritinib
• Synonyme: 14,19-Dioxa-5,7,27-triazatetracyclo[19.3.1.12,6.18,12]heptacosa-1(25),2,4,6(27),8,10,12(26),16,21,23-decaene, 11-[2-(1-pyrrolidinyl)ethoxy]-, (16E)-, (16E)-11-[2-(1-Pyrrolidinyl)ethoxy]-14,19-dioxa-5,7,27-triazatetracyclo[19.3.1.12,6.18,12]heptacosa-1(25),2,4,6(27),8,10,12(26),16,21,23-decaene, SB 1518

Beschreibung

Pacritinib is a selective inhibitor of the tyrosine kinase JAK2. It has been shown to be effective against colorectal adenocarcinoma, hepatic steatosis, and minimal toxicity in preclinical trials. Pacritinib inhibits the activity of JAK2, which is an enzyme that participates in the signaling pathways of cytokines and growth factors that are involved in immune responses and cell proliferation. This drug may have potential for the treatment of infectious diseases, such as tuberculosis and leishmaniasis, as well as autoimmune diseases such as psoriasis and rheumatoid arthritis. Pacritinib is currently undergoing clinical trials for the treatment of various types of cancer, psoriasis, rheumatoid arthritis, Crohn's disease, ulcerative colitis, and other immune-mediated disorders.

• Marke: Biosynth

Chemische Eigenschaften

• Molekulargewicht: 472.59 g/mol
• Formel: C₂₈H₃₂N₄O₃
• Reinheit: Min. 95%